Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Editas Medicine, Inc. - Common Stock (NQ:EDIT)

2.470 -0.050 (-1.98%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,100,123
Open 2.620
Bid (Size) 2.420 (700)
Ask (Size) 2.500 (100)
Prev. Close 2.520
Today's Range 2.410 - 2.730
52wk Range 0.9101 - 4.537
Shares Outstanding 81,632,619
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Editas Medicine Inc (NASDAQ:EDIT) Beats Q3 2025 Estimates and Provides Key Pipeline Update ↗
Editas Medicine beats Q3 2025 earnings estimates, reports strong revenue growth, and advances its lead gene-editing program, EDIT-401. 
Via Chartmill
News headline image
Editas Medicine Announces Third Quarter 2025 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire

Performance

YTD
+88.5%
+88.5%
1 Month
-36.3%
-36.3%
3 Month
-9.5%
-9.5%
6 Month
+52.5%
+52.5%
1 Year
+2.5%
+2.5%

More News

Read More
News headline image
AI Unlocks Gene-Editing Revolution: $2 Million Grant Propels Disease Cures
Via TokenRing AI
Topics Artificial Intelligence Climate Change Intellectual Property
News headline image
Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Intellia Freezes Key Trial After Serious Liver Event, Stock Tumbles ↗
Via Benzinga
News headline image
Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine Inc (NASDAQ:EDIT) Shows High Growth Momentum and Strong Technical Trend ↗
Via Chartmill
News headline image
Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years ↗
Via Benzinga
News headline image
Editas Medicine Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗
Via Benzinga
News headline image
Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine to Participate in Upcoming Investor Conferences
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Why Editas Medicine Stock Was Skyrocketing This Week ↗
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Via Benzinga
News headline image
Top movers in Wednesday's session ↗
Via Chartmill
News headline image
Wednesday's session: gap up and gap down stocks ↗
Via Chartmill
News headline image
Editas Medicine Inc (NASDAQ:EDIT) Reports Mixed Q2 2025 Earnings: Revenue Beat but Wider Loss ↗
Via Chartmill
News headline image
Editas Medicine Announces Second Quarter 2025 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Can This Beaten-Down Stock Bounce Back? ↗
Via The Motley Fool
News headline image
Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now? ↗
Via The Motley Fool
Topics Workforce
News headline image
2 Beaten-Down Stocks to Avoid ↗
Via The Motley Fool
News headline image
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst ↗
Via Benzinga
News headline image
Editas Medicine Is Great. Here's Why You Shouldn't Buy It. ↗
Via The Motley Fool
News headline image
Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover ↗
Via Investor's Business Daily

Frequently Asked Questions

Is Editas Medicine, Inc. - Common Stock publicly traded?
Yes, Editas Medicine, Inc. - Common Stock is publicly traded.
What exchange does Editas Medicine, Inc. - Common Stock trade on?
Editas Medicine, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Editas Medicine, Inc. - Common Stock?
The ticker symbol for Editas Medicine, Inc. - Common Stock is EDIT on the Nasdaq Stock Market
What is the current price of Editas Medicine, Inc. - Common Stock?
The current price of Editas Medicine, Inc. - Common Stock is 2.470
When was Editas Medicine, Inc. - Common Stock last traded?
The last trade of Editas Medicine, Inc. - Common Stock was at 11/20/25 04:00 PM ET
What is the market capitalization of Editas Medicine, Inc. - Common Stock?
The market capitalization of Editas Medicine, Inc. - Common Stock is 201.63M
How many shares of Editas Medicine, Inc. - Common Stock are outstanding?
Editas Medicine, Inc. - Common Stock has 202M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.